Myeloperoxidase polymorphism and coronary artery disease risk: A meta-analysis

The myeloperoxidase (MPO) gene 463G/A and 129G/A polymorphisms have been reported to be associated with coronary artery disease (CAD), but the results remain inconclusive. This meta-analysis was designed to clarify these controversies. PubMed, EMBASE, and the Cochrane Library were used to retrieve the relevant literature up to March 2015 according to keywords. A total of 8 case–control studies, including 3491 cases and 7293 controls, were included in this meta-analysis. Summary odds ratios (ORs) and their corresponding 95% confidence intervals (CIs) were calculated. There was strong evidence of an association between the MPO 463G/A polymorphism and CAD. The data revealed that only the dominant model was associated with CAD (dominant model: OR = 0.872, 95% CI = 0.77–0.99). Regarding the 129G/A gene polymorphism, the pooled OR for the genotype AA + AG versus GG was 0.906 (95% CI = 0.74–1.10). This meta-analysis suggested an association between the MPO 463G/A polymorphism and the risk of CAD, but there is no significant association between the MPO 129G/A gene polymorphism and CAD risk.